 Home > Active Ingredient News > Antitumor Therapy > Lancet oncol: Atolizumab combined with bevacizumab can significantly improve the quality of life reported by patients with advanced liver cancer

Lancet oncol: Atolizumab combined with bevacizumab can significantly improve the quality of life reported by patients with advanced liver cancer

 Last Update: 2021-06-01
 Source: Internet
 Author: User

Tags

risk ratio ldl hdl

dexamethasone 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

It is important to understand the patient's cancer treatment experience.

This study aims to evaluate the prognosis (PRO) reported by patients in the IMbrave150 trial.

The IMbrave150 trial is an open-label, randomized phase 3 trial conducted in 111 hospitals/cancer centers in 17 countries/regions.

From March 15, 2018 to January 30, 2019, a total of 725 patients were screened , of which 501 were recruited into the group and randomly assigned to the combination group (n=336) or sorafenib group (n= 165).

Screening

Changes in EORTC QLQ-C30 quality of life and functional scale assessment results during the first 5 courses of treatment in each treatment group

As of August 29, 2019, the median follow-up was 8.

The median follow-up was 8.

Compared with sorafenib, atuzumab combined with bevacizumab treatment can reduce the risk of deterioration of the predetermined EORTC QLQ-C30 general cancer symptom scale and also reduce three EORTC QLQ-HCC18 disease-specific symptom scales Risk of deterioration of two of them

In summary, a scheduled analysis of PRO data shows that compared with sorafenib, patients treated with atolizumab combined with bevacizumab have reported clinically significant benefits in terms of quality of life, function, and disease symptoms.

Compared with sorafenib, patients treated with atolizumab combined with bevacizumab have reported clinically significant benefits in terms of quality of life, function, and disease symptoms

Original source:

Peter R Galle, et al.

org/10.
1016/S1470-2045(21)00151-0" target="_blank" rel="noopener">Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.